This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yokoi, A. Articles by Owa, T. Search for Related Content PubMed PubMed Citation Articles by Yokoi, A. Articles by Owa, T.

Laboratory of Seeds Finding Technology [A. Y., J. K., T. K., T. N., T. O.], Discovery Research Laboratories II [N. H. S., K. Y.], and Exploratory Research Laboratories [H. Y.], Eisai Co. Ltd., Ibaraki 300-2635, Japan

A series of small molecules from sulfonamide-focused libraries have been evaluated in these laboratories to discover novel antitumor agents. Cell-based screens using flow cytometric analysis revealed the presence of two distinct classes of cell cycle inhibitors in this series; one (including E7010 and ER-67865) arrested mitosis by preventing tubulin polymerization; and the other (including E7070 and ER-68487) caused a decrease in the S-phase fraction along with cell cycle perturbation in G₁ and/or G₂ via an unknown mechanism(s). To further characterize both classes of antitumor sulfonamides with respect to their effects on gene expression, we used oligonucleotide microarray analysis for representative compounds. Consistent with the phenotypic observations, essentially the same transcription profiles were found between E7010 and ER-67865 and also between E7070 and ER-68487. However, there was very little overlap between genes affected by E7010 and E7070. As a characteristic expression change for microtubule-depolymerizing agents, the down-regulation of -tubulin transcripts was evident in both E7010- and ER-67865-treated cells. On the other hand, E7070 and ER-68487 repressed significantly the expression of a variety of genes involved in metabolic processes, cell cycle progression, immune response, and signal transduction. Of the compounds examined, E7010 and E7070 have progressed to clinical trials, demonstrating some objective responses in the Phase I setting. Described herein is profiling of novel anticancer drug candidates from the sulfonamide class based on phenotypic screens and gene expression analysis. This includes a translational research that may suggest potentially useful markers for pharmacodynamic drug assessment in clinic.

This article has been cited by other articles:

				E. Fox, J. M. Maris, B. C. Widemann, K. Meek, A. Goodwin, W. Goodspeed, M. Kromplewski, M. E. Fouts, D. Medina, S. Y. Cho, et al. A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. Clin. Cancer Res., August 15, 2006; 12(16): 4882 - 4887. [Abstract] [Full Text] [PDF]

				R. I. Haddad, L. J. Weinstein, T. J. Wieczorek, N. Bhattacharya, H. Raftopoulos, M. W. Oster, X. Zhang, V. M. Latham Jr., R. Costello, J. Faucher, et al. A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck: Modulation of Retinoblastoma Protein Phosphorylation by a Novel Chloroindolyl Sulfonamide Cell Cycle Inhibitor Clin. Cancer Res., July 15, 2004; 10(14): 4680 - 4687. [Abstract] [Full Text] [PDF]

				J. Z. Pan, R. Jornsten, and R. P. Hart Screening anti-inflammatory compounds in injured spinal cord with microarrays: a comparison of bioinformatics analysis approaches Physiol Genomics, April 13, 2004; 17(2): 201 - 214. [Abstract] [Full Text] [PDF]